Las Vegas, NV -- (SBWIRE) -- 12/12/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is on: PMC-Sierra Inc (NASDAQ:PMCS), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Acacia Research Corp (NASDAQ:ACTG), Amkor Technology, Inc. (NASDAQ:AMKR)
PMC-Sierra Inc (NASDAQ:PMCS) managed to keep its fall at -1.16% on below -normal volume of 1.45M shares. The stock settled at $5.95 after floating in a range of $5.93 to $610. Its latest price has reached market capitalization of $1.21 billion. Its 52-week range has been $5.09 to $7.14. PMC-Sierra, Inc., is a semiconductor innovator transforming networks that connect, move and store digital content. The Company designs, develops, markets and supports semiconductor solutions by integrating its mixed-signal, software and systems through a network of offices in North America, Europe and Asia. It had approximately 700 different semiconductor devices that were sold to equipment and design manufacturers, who in turn supply their equipment principally to service providers, carriers and enterprises globally. In July 2013, PMC-Sierra Inc completed the purchase of Integrated Device Technology, Inc.’s (IDT) Enterprise Flash Controller business including the NVM Express (NVMe) flash controller.
Has PMCS Found The Bottom and Ready To Move Up? Find Out Here
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded down on a volume of 1.41 million, lower than its standard daily volume. Shares have dropped-5.55% to $22.29. Over the last twelve months, the stock has lost-8.61% and faced a worst price of $1.41. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin.
Has ACAD Found The Bottom And Ready To Gain Momentum? Find Out Here
Acacia Research Corp (NASDAQ:ACTG) settled -1.71% lower at $12.68 on above-normal volume of 1.39M shares during the last trading day. The stock has its 12-month high at $32.59 and 52-week low price was $12.23. It traded in a range of $12.23 to $12.94 during the last trading day. Acacia Research Corporation through its operating subsidiaries, acquires, develops, licenses and enforces patented technologies. The Company’s operating subsidiaries generate revenues and related cash flows from the granting of rights for the use of patented technologies, which its operating subsidiaries own or control. Its operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use.
Will ACTG Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Amkor Technology, Inc. (NASDAQ:AMKR) was down on high volume, trading at a volume of 1.39M shares versus its average daily volume of 1.09 million shares. At $5.51, the stock has attained market capitalization of $1.19 billion. Amkor Technology, Inc. (Amkor) is a provider of outsourced semiconductor packaging (assembly) and test services. The Company offers a range of packaging and test technologies and services. Its packages are designed based on application and chip specific requirements, including the type of interconnection technology employed, size, thickness, and electrical, mechanical and thermal performance. It provides turnkey packaging and test solutions, including semiconductor wafer bump, wafer probe, wafer backgrind.
Why Should Investors Buy AMKR After the Recent Fall? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)